13 results about "Myeloperoxidase" patented technology

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

A compound of formula (I), and a preparation method therefor and a use thereof in medicine. Specifically, the present invention provides a compound of formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, and also relates to a pharmaceutical composition containing the compound and a use of the compound in the preparation of a drug for treating and / or preventing cardiovascular diseases. The compound is an inhibitor for myeloperoxidase (MPO).

The invention provides an anti-neuroinflammation medicine as well as a preparation method and application thereof. The anti-neuroinflammation medicine comprises an active component and lipidosome, the active component is an inhibitor 4-aminobenzoyl hydrazine of myeloperoxidase; the liposome is prepared from phospholipid, cholesterol and distearoyl phosphatidyl ethanolamine-thioketal-polyethylene glycol; the method comprises the following steps: weighing lipidosome and 4-aminobenzoyl hydrazine, dissolving, and carrying out rotary evaporation to obtain a lipid membrane; adding a phosphate buffer solution into the lipid membrane, stirring in a water bath, performing ultrasonic treatment, filtering, centrifuging and purifying to obtain the medicine, according to the active oxygen response-based liposome delivery system disclosed by the invention, 4-aminobenzoyl hydrazine is encapsulated in liposome to form a drug, and after the drug enters a brain inflammation microenvironment area of the Alzheimer's disease, the active oxygen can break a thioketal bond, so that local release of 4-aminobenzoyl hydrazine is triggered, targeted inhibition of myeloperoxidase is realized, and the drug delivery effect is improved. The oxidative stress level is reduced, the neuroinflammation is relieved, and the cognitive impairment is effectively improved.

The application belongs to the technical field of chemical drugs, and particularly relates to a pyrazole compound and a preparation method and application thereof. The application provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, which not only has good myeloperoxidase (MPO) inhibitory activity, but also can be used for treating and / or preventing cardiovascular diseases. (I)

Provided herein are compounds useful as imaging agents. Exemplary compounds provided herein are useful as myeloperoxidase imaging agents using positron emission tomography or fluorescence imaging techniques. Methods for preparing the compounds provided herein and diagnostic methods using radiolabeled arid unlabeled compounds are also provided.

The application provides a fluorescent probe for myeloperoxidase detection, and a preparation method and application thereof. The fluorescent probe can detect MPO in living cells, greatly shortens the detection time, has low production cost, high specificity, and can be fixed on the protein of the cell after response, thereby avoiding non-specific fluorescent signal transmission and reducing false positives in the detection process. Meanwhile, the fluorescent probe can realize the function of distinguishing myeloid leukemia cells from lymphoid leukemia cells.

There are disclosed certain 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one compounds of formula (I),and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disorders such as heart failure and coronary artery disease related conditions.

This invention discloses a sulfur-containing 5-aminosalicylic acid prodrug and its uses, belonging to the field of biomedical technology. The sulfur-containing 5-aminosalicylic acid prodrug of this invention has the structure shown in general formula I. This type of compound has good intervention effects on inflammation-related diseases, exhibiting more ideal anti-inflammatory activity than 5-ASA and sulfasalazine. It can also inhibit the production of hypochlorous acid and related inflammatory mediators by inhibiting myeloperoxidase (MPO), and can be used to prepare drugs for the prevention and / or treatment of inflammatory bowel disease, and drugs for the prevention and / or treatment of diseases related to abnormal oxidative stress.

The invention discloses a synthesis method and application of a mitochondrial division inhibitor 1 with myeloperoxidase responsiveness and fluorescence biological imaging capability, the mitochondrial division inhibitor 1, 5-hydroxytryptamine and carbon quantum dots are integrated through a chemical bonding method, and a novel multifunctional nano system CDs-5HT-Mdivi-1 is obtained. The synthesized CDs-5HT-Mdivi-1 is of a lattice structure, the diameter is 2.51 + / -0.88 nm, the height is 2.5 nm, the surface potential is 16.01 + / -0.78 mV, medicine targeted accumulation, synergistic interaction and diagnosis and treatment integration under MPO triggering can be achieved, myocardial infarction can be treated in a targeted mode, and myocardial ischemia reperfusion injury can be improved.

This disclosure relates to a method for identifying subjects likely to respond to treatment with myeloperoxidase (MPO) inhibitors based on neutrophil levels and / or concentrations of at least one protein biomarker. This disclosure further relates to a method for selecting subjects for treatment with MPO inhibitors, a method for predicting whether subjects will respond to treatment with MPO inhibitors, and a method for treating subjects likely to respond to treatment with MPO inhibitors. This disclosure further relates to a method for predicting improved clinical response in subjects with MPO-related disorders after treatment with MPO inhibitors.

This invention discloses a myeloperoxidase-responsive fluorescent probe liposome, its preparation method, and its applications. The raw materials for this fluorescent probe liposome include lecithin, cholesterol, collagen, luminol, and Cy5. These raw materials are prepared using a thin-film dispersion method to obtain the fluorescent probe liposome. This invention combines luminol with Cy5, solving the problem of low sensitivity or even undetectability of luminol to deep inflammatory foci in body tissues. It enables imaging detection of deep inflammatory cells in the body, which has significant application value in evaluating inflammatory responses caused by tumors, epilepsy, etc., and is of great significance for guiding clinical treatment of tumors and epilepsy and assessing efficacy.

The present invention relates to granulocyte precursor cell that has been differentiated in vitro, wherein the granulocyte precursor cell comprises: (a) increased expression of one or more of: serglycin (SRGN), myeloperoxidase (MPO), major histocompatibility complex, class II, DR alpha (HLA-DRA), CD74, and elastase (ELANE) when compared to an equivalent granulocyte precursor cell that has been differentiated in vivo; and / or (b) decreased expression of one or more of: defensin alpha 1 (DEFA1), defensin alpha 3 (DEFA3), cathelicidin antimicrobial peptide (CAMP), bactericidal permeability increasing protein (BPI), and azurocidin 1 (AZU1) when compared to an equivalent granulocyte precursor cell that has been differentiated in vivo. Also provided are cells, methods for producing the same, uses of the same, and kits comprising the same.

The invention discloses a preparation method and application of a dual-targeting hepatocellular carcinoma nano-drug, and belongs to the field of biological medicines. According to the invention, a double-targeting target molecule with myeloperoxidase-asialoglycoprotein receptor double-targeting property is synthesized, and the double-targeting target molecule is modified on a covalent organic nano molecule COF-366 through pi-pi stacking, wherein the covalent organic nano molecule COF-366 is coated with chemotherapeutic drugs sorafenib and chloroquine and has photodynamic characteristics. The obtained nano-drug can be gradually delivered to hepatocytes under the guidance of double-targeting molecules, drug release is started in acidity of a tumor acidic microenvironment, the synergistic treatment effect of photodynamic therapy and chemotherapy can be played, and the synergistic effect causes tumor injury, so that the inflammation targeting of the nano-drug is further enhanced. The nano-drug has good stability and biological safety, in-vivo behavior tracing and treatment efficacy evaluation are carried out in subcutaneous solid tumor and in-situ tumor mouse models, and the nano-drug is expected to play a huge role in clinical application.